Hepatitis C Research Opportunities in Houston: Greater New Drug Availability by Dr.Joe Galati on August 20, 2011
Over the past several weeks, those of you interested in the new hepatitis C treatments that have been recently FDA approved, have been delighted with the opportunity to finally have new options to treat your hepatitis C infection.The release of Boceprevir (marketed as Victrelis by Merck) and Telaprevir (Incivek by Vertex) has marked a major breakthrough in managing hepatitis C.Despite this breakthrough in care, research continues in developing new, and more potent anti-virals to eliminate the hepatitis c virus.The breakthroughs made with the newly release protease inhibitors Boceprevir and Telaprevir are being followed by continued research and development of second generation protease inhibitors, polymerase inhibitors, and an a*sortment of novel drugs and compounds.
I returned yesterday from an investigators meeting in Denver, where we discussed a new drug against hepatitis C developed by Bristol-Meyers Squibb.The compound, BMS-790052, is a once a day NS5A inhibitor, combined with interferon and ribavirin.The study we are conducting with this drug is titled:
Open-Label, Single Arm Evaluation of BMS-790052 in Combination with Peg-Interferon Alfa-2a and Ribavirin in Black-African Americans, Latinos, and White-Caucasians with Chronic Hepatitis C Genotype 1 Infection.
This is an important study because it is looking at African Americans and Latino patients with chronic hepatitis C infection.Many important questions will be answered during the course of this study.I am pleased to be participating in this study.
If you are interested in participating in this study, or any other hepatitis C research studies we are participating in, fill out the form located at this link.
Listed below is a complete list of studies we are participating in.Feel free to contact us for more information on these studies and hepatitis C.
1-A Multi-Center, Open Label Trial to Evaluate the Long-Term Safety and Tolerability of Rifaximin 550 mg BID in Subjects with A History of Hepatic Encephalopathy.Salix
2-Protocol HGS1008-C1060: A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or PEG-IFNО
